Category: News

AAV industry veteran Anna Tretiakova, PhD, has joined AskBio as SVP, Product Development to lead preclinical translational research.

AskBio today introduced AskFirst™, its patient advocacy program for patients and their families, and announced that Matthew Alsante will lead the program.

AskBio today announced that Sheila Mikhail, AskBio’s Chief Executive Officer and Co-founder, has been invited to provide an overview of the company at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, in San Francisco.

AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and potentially enable re-treatment of patients with Pompe disease.

Recognition highlights $235 million investment fueling growth of company and its industry-leading gene therapy technology platform

Scientific leaders in cell and gene therapy collaborate to determine efficacy of SQZ tolerizing antigen carriers (TACs) containing AAV components to overcome patient immune responses to AAV

National award recognizes outstanding entrepreneurial women who lead high-growth companies that are transforming their industries

Editas and AskBio, today announced the companies have entered a strategic research collaboration to explore in vivo delivery of genome editing medicines to treat neurological diseases.

Expands AAV gene therapy platform from inside the cell for genetic disorders

Certification confirms Viralgen’s commitment to high operational standards with the world’s most flexible and robust AAV manufacturing capability